Core Viewpoint - As of December 31, 2025, the company reported a significant decline in total revenue, dropping from RMB 981 million in 2024 to RMB 574 million in 2025, a decrease of RMB 407 million or 41.5% [1] Revenue Breakdown - The primary reason for the revenue decline was the recognition of RMB 678 million in intellectual property income during the fiscal year ending December 31, 2024 [1] - Product sales revenue and commercialization rights income increased by 90% year-on-year, reaching RMB 574 million [1] - Sales revenue for the drug Nairike (Aurebacitin) in the Chinese market grew by 81%, from RMB 241 million in 2024 to RMB 435 million in 2025 [1] - The drug Lisentuo (Lisatrag) received approval from China's NMPA in early July 2025 and achieved sales revenue of RMB 70.58 million in the last five months of 2025 [1] Clinical Research - The company is conducting nine Phase III clinical trials globally, with four of them having received approvals from the US FDA and the European EMA [1]

Group 1 - The core point of the article highlights the paradox of a pharmaceutical company experiencing over 1.296 billion yuan in losses while its core product sales surged by 81%, illustrating the typical development logic of innovative pharmaceutical companies during their commercialization expansion phase [1] - The company has adopted a "dual-engine" strategy, focusing on rapid market expansion of core products through medical insurance while simultaneously increasing global clinical development and R&D investments [1][3] Group 2 - In 2025, the company achieved product sales and commercialization rights revenue of 574 million yuan, a 90% year-on-year increase, with the core product, Aorebatin (耐立克), generating 435 million yuan in sales, reflecting an 81% growth [3] - The second commercialized product, Lisatoclax (利生妥), was approved for market launch in July 2025 and contributed 70.58 million yuan in revenue within just five months [3] - Despite the significant revenue growth, the company remains in an investment phase, with sales and distribution expenses reaching 354 million yuan (up 80.4%) and R&D expenses at 1.137 billion yuan (up 20.1%) in 2025 [3] Group 3 - The company's trajectory represents a narrative of persistence and breakthrough, reflecting the broader industry shift from generic to innovative drug development in the context of China's pharmaceutical landscape [4]

Core Insights - The company achieved total revenue of 574 million RMB in 2025, driven by strong commercialization growth [1] - The first commercial product, Nairike (Aorebatin), saw significant sales growth of 435 million RMB, an increase of 81% year-on-year [1] - The second product, Lishengtuo (Lisatrakra), generated sales of 70.58 million RMB within five months of its approval in July 2025 [1] - The company reported a total cash position of approximately 2.47 billion RMB, indicating improved cash flow [1] Global Clinical Development - The company achieved milestone breakthroughs with global Phase III studies for Nairike in treating Ph+ ALL and Lishengtuo for high-risk MDS, both receiving approvals from the FDA and EMA in 2025 [1] - Multiple Phase III clinical studies are currently underway globally, with four studies having received FDA and EMA approvals [1] Commercialization and Team Expansion - The commercialization team expanded rapidly, exceeding 270 personnel by the end of 2025, covering over 1,500 hospitals nationwide [2] - The company successfully listed on NASDAQ in January 2025, becoming the first biopharmaceutical company to have a dual primary listing in Hong Kong and the U.S. [2] Strategic Vision - The CEO emphasized that 2025 was a pivotal year for the company's global expansion, achieving breakthroughs in commercialization, clinical development, pipeline innovation, and capital markets [2] - The company aims to focus on unmet patient needs and accelerate global clinical development of core products, aspiring to become a global leader in the field of hematologic oncology innovation [2]

Core Insights - The company Aiyang Pharmaceutical (06855.HK / AAPG.OQ) has several key business milestones to watch for in 2026, focusing on core product commercialization, global clinical advancements, and breakthroughs in its innovative pipeline [1] Performance and Operations - The product APG-2575, China's first domestic Bcl-2 inhibitor, is set to participate in the national medical insurance catalog negotiations in 2026, which, if successful, could enhance market penetration [2] - The third-generation BCR-ABL inhibitor, Nilotinib, is expected to accelerate sales following the expansion of medical insurance coverage, with a target to cover over 1,500 hospitals, thereby increasing patient accessibility [2] Project Progress - The POLARIS-1 study, a global Phase III clinical trial for Ph+ acute lymphoblastic leukemia (Ph+ ALL), is planned to initiate patient enrollment in Europe and the U.S. in 2026, laying the groundwork for a 2028 submission to the FDA/EMA [3] - The POLARIS-2 study, targeting third-line and above chronic myeloid leukemia (3L+ CML), is expected to complete enrollment in 2026, with primary endpoints including 6-month cytogenetic response (CCyR) and major molecular response (MMR), potentially becoming the first domestically developed third-generation BCR-ABL inhibitor submitted overseas [3] Research Developments - The GLORA series studies, including the GLORA Phase III trial for first-line CLL/SLL, aims to complete enrollment in 2026, with a new drug application (NDA) submission planned for 2027 [4] - The GLORA-4 study for high-risk myelodysplastic syndromes (MDS) is set to release key data in 2026, addressing a treatment gap that has persisted for nearly 20 years without new drug approvals [4] - APG-2449, a third-generation ALK-TKI for resistant non-small cell lung cancer (NSCLC), is expected to present preliminary data in 2026, with potential to become a best-in-class product [4] Product Development Progress - APG-3288, a BTK degrader based on PROTAC technology, received clinical trial approval in China and the U.S. in February 2026, with a global multi-center Phase I study initiated, aiming to obtain preliminary pharmacokinetic and safety data in 2026 [5] - APG-115, an MDM2-p53 inhibitor, is in the second stage of global development, with critical data expected in 2026 that could influence its competitive landscape [6] - APG-5918, an EED inhibitor, is expanding into the anemia field, with clinical trials in oncology and non-oncology indications planned for 2026 in China and the U.S. [7]

Group 1 - The core viewpoint is that multiple institutions maintain a positive rating for Ascentage Pharma-B (06855.HK), with 100% of market opinions suggesting buy or hold positions [1] - CICC's report from December 2025 highlights that the global Phase III study POLARIS-1 for Olverembatin (耐立克) has received approval from both the FDA and EMA, and the clinical data for APG-2575 (利生妥) is impressive, maintaining a target price of HKD 89 [1] Group 2 - Over the past 7 days (as of February 20, 2026), Ascentage Pharma-B's stock price fluctuated, closing at HKD 47.46 on February 20, a slight decrease of 0.08% from HKD 46.68 on February 16, with a trading range of 4.55% [2] - During the same period, the US stock (AAPG.OQ) closed at USD 24.34, reflecting a cumulative increase of 2.18% [2] - Capital flow data indicates a net inflow of HKD 993,600 into the Hong Kong stock market on February 20, with overall trading activity being light [2]

Core Insights - The article emphasizes the significant advancements and global presence of Chinese companies in the biopharmaceutical sector, particularly at the JPM 2026 conference, showcasing their capabilities in both service and innovation [7][10]. Group 1: Chinese Companies at JPM 2026 - WuXi Biologics reported a substantial increase in its CRDMO business, achieving 209 comprehensive project collaborations by 2025, up from 150 in 2024, with a focus on complex projects like bispecific antibodies and ADCs [7][8]. - Ascentage Pharma highlighted its global innovation pipeline, featuring key products like the third-generation BCR-ABL inhibitor and BCL-2 inhibitor, which are driving growth in hematological oncology [9]. - Approximately 24 Chinese innovative pharmaceutical companies presented their clinical data and R&D progress at the conference, indicating a shift from being followers to systemic innovators in the global market [9][10]. Group 2: Multinational Pharmaceutical Companies - AbbVie projected an 8% revenue growth for 2025, with a 19% increase in sales from growth platforms, emphasizing the potential of its core immunology products [11]. - Sanofi reiterated its commitment to commercializing respiratory and vaccine-related assets while enhancing its pipeline through external collaborations [11]. - Gilead focused on its long-term strategy in virology, aiming for extended dosing forms and broader disease coverage [12]. Group 3: Healthcare Services and Capital Markets - The third day of the conference saw a shift towards discussions on cash flow, asset quality, and operational resilience among healthcare systems, with many reporting progress in cost control and operational integration [13]. - There was a cautious approach to mergers and acquisitions, with executives indicating a preference for manageable, cash-flow-positive targets rather than high-premium, long-cycle assets [13]. Group 4: Overall Conference Signals - The overall tone of the conference shifted towards practicality, focusing on verifiable results and execution capabilities rather than speculative narratives [14].

Company Updates - The company announced that the global registration Phase III study POLARIS-1 for Narlik (Orelabrutinib) in 1L treatment of Ph+ ALL has received approval from the US FDA and European EMA [1] - The company will present multiple data sets for three products at the 2025 American Society of Hematology (ASH) annual meeting in December, including oral reports on domestic Phase II registration clinical data for Lisengrat (APG-2575) and the first readout of POLARIS-1 data [1] Clinical Data Highlights - POLARIS-1 has become the second global registration Phase III study for Narlik approved in Europe and the US, with preliminary data showing that as of July 18, 2025, 94.3% of 53 1L Ph+ ALL patients achieved CR/CRi within three months, with best MRD negative rates and MRD negative CR rates at 66.0% and 64.2% respectively [1] - Lisengrat demonstrated good efficacy in a high-risk population for R/R CLL/SLL, with an ORR of 62.5% and mPFS of 23.89 months as of July 25, 2025, with 21.8% achieving MRD negativity [2] - The combination of Lisengrat and Azacitidine in R/R AML/MPAL patients showed an ORR of 40.4% and CR of 29.8%, while in newly diagnosed high-risk MDS/CMML patients, the ORR was 80.0% [2] Financial Forecast and Valuation - The company maintains its net profit forecast for 2025 and 2026 at -1.09 billion and -0.30 billion respectively, and continues to outperform the industry model [2] - Based on DCF valuation, the target price is maintained at 89 HKD, indicating a potential upside of 56.3% from the current stock price [2]

Company Overview - CICC maintains a "outperform" rating and a target price of HKD 89 for Ascentage Pharma-B (06855), highlighting positive recent R&D progress [1] - The global Phase III study (POLARIS-1) of Olverembatinib (耐立克) for first-line treatment of Ph+ ALL has received approval from both the FDA and EMA [2] - The company is set to present multiple data points at the 2025 American Society of Hematology (ASH) annual meeting, including domestic Phase II clinical data for APG-2575 and initial results from POLARIS-1 [2] R&D Progress - POLARIS-1 data shows that as of July 18, 2025, 94.3% of 53 first-line Ph+ ALL patients achieved CR/CRi within three months, with best MRD negative rates at 66.0% and MRD negative CR rates at 64.2% [2] - The company views Olverembatinib as its first commercial product, with steady expansion of indications and promising data readouts [2] APG-2575 Efficacy - APG-2575 demonstrated a 62.5% overall response rate (ORR) in 72 R/R CLL/SLL patients, with a median progression-free survival (mPFS) of 23.89 months and 21.8% achieving MRD negativity [3] - Notably, nearly half of the patient population had complex chromosomal abnormalities, indicating a higher risk profile and underscoring the drug's efficacy potential [3] Combination Therapy Data - The combination of APG-2575 and Azacitidine showed an ORR of 40.4% in 47 R/R AML/MPAL patients, with a complete response (CR) rate of 29.8% and mPFS of 7.6 months [4] - In 15 newly diagnosed high-risk MDS/CMML patients, the ORR was 80.0%, with CR and bone marrow CR rates at 40%, although mPFS was not reached [4]

Company Overview - CICC maintains a "outperform" rating and a target price of HKD 89 for Ascentage Pharma-B (06855), citing positive recent R&D progress [1] - The global Phase III study (POLARIS-1) for Nilotinib (Orelabrutinib) as a first-line treatment for Ph+ ALL has received approval from both the FDA and EMA [1][2] - The company plans to present multiple data points for three products at the 2025 American Society of Hematology (ASH) annual meeting, including oral reports on APG-2575's domestic Phase II registration clinical data and the first readout of POLARIS-1 data [1] POLARIS-1 Study Results - The POLARIS-1 study shows promising initial data, with 94.3% of 53 first-line Ph+ ALL patients achieving complete response (CR) or complete response with incomplete blood count recovery (CRi) within three months [2] - The best minimal residual disease (MRD) negative rate and MRD negative CR rate were reported at 66.0% and 64.2%, respectively [2] APG-2575 Efficacy in High-Risk Populations - APG-2575 demonstrated a 62.5% overall response rate (ORR) in 72 patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL), with a median progression-free survival (mPFS) of 23.89 months [3] - Notably, nearly half of the patient population had complex chromosomal abnormalities, indicating a higher risk profile, which underscores the drug's potential efficacy [3] Combination Therapy Data - The combination of APG-2575 and Azacitidine showed an ORR of 40.4% in 47 patients with R/R acute myeloid leukemia/mixed phenotype acute leukemia (AML/MPAL), with a complete response (CR) rate of 29.8% and mPFS of 7.6 months [4] - In 15 patients with newly diagnosed high-risk myelodysplastic syndromes/chronic myelomonocytic leukemia (MDS/CMML), the ORR was 80.0%, with CR and bone marrow CR rates of 40% [4]

Core Viewpoint - The announcement highlights the approval of the global Phase III clinical trial (POLARIS-1) for the novel drug Orebatin (brand name: Nairike) in treating newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients, which is expected to accelerate its market entry in Europe and the US [1][2]. Group 1: Clinical Trial Details - POLARIS-1 is an international, multicenter, randomized, open-label Phase III clinical trial aimed at evaluating the efficacy and safety of Nairike in combination with chemotherapy for newly diagnosed Ph+ ALL patients [1]. - The trial has received clinical trial approval from China's CDE in 2023 and has been rapidly initiated [1]. Group 2: Efficacy and Safety Data - Preliminary data from the POLARIS-1 study indicates that the molecular minimal residual disease (MRD) negative rate and complete response (CR) rate for patients treated with Nairike and low-intensity chemotherapy are approximately 65%, significantly higher than similar products under comparable conditions [2]. - The safety profile of the combination treatment is favorable, with a low and manageable incidence of adverse effects [2]. Group 3: Market Context and Product Background - Ph+ ALL accounts for about 20%-30% of adult ALL cases, characterized by high relapse rates and poor prognosis, particularly in older patients [2]. - Nairike is a third-generation TKI and the first of its kind approved in China, with commercial promotion in China being jointly managed by the company and Innovent Biologics [3]. - The drug has received multiple indications for treatment in the CML resistant field and is included in the national medical insurance drug list [3].